Floatz logo

CRENIGACESTAT

Recurrent Plasma Cell Myeloma

Fred Hutchinson Cancer CenterSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

498 Active assets in the Recurrent Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

CRENIGACESTAT is also rated in:

T lymphoblastic leukemia/lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
T-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
soft tissue sarcomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →